Weekend Reading
11/23/25
Week of November 23, 2025
Fed divisions deepen, nuclear momentum accelerates, and healthcare emerges as the market’s defensive anchor. This week’s developments suggest a bifurcated investment landscape where policy uncertainty collides with structural tailwinds in energy and healthcare.
Macro: Fed at a Crossroads
The Federal Reserve enters its blackout period with an uncommon degree of internal dissent that markets have only begun to price. October FOMC minutes reveal a committee split on December’s path, with “several participants” supporting a 25 basis point cut if economic evolution meets expectations, while “many participants” view maintaining the 3.75%-4.00% range as appropriate through year-end. This division isn’t merely academic—Capital Economics sketches a plausible 6-6 tie scenario at the December meeting, an outcome without modern precedent.
Market pricing has whipsawed accordingly. Interest rate futures swung from 39% to 75% probability for a December cut following New York Fed President John Williams’ explicit endorsement of near-term easing, while Boston Fed’s Susan Collins countered that policy is “in the right place”. The underlying calculus has grown murkier: October CPI data won’t arrive until December 18, after the FOMC decision, due to Bureau of Labor Statistics delays. This data vacuum leaves the Fed flying partially blind into its final meeting of 2025.
Investment Implication: The balance of risks skews toward volatility. With the Fed’s balance sheet runoff concluding December 1 and reinvestment mechanisms shifting toward Treasury bills, liquidity conditions should ease modestly. However, the combination of a divided committee and absent inflation data creates a binary outcome for December 10, either a cut that validates current equity valuations or a hold that forces repricing of the Fed’s reaction function.
International developments compound the uncertainty. S&P Global revised China’s 2025 growth forecast upward to 5.0% on export resilience and pro-growth policy signals, while UK gilts underperformed amid concerns that Chancellor Reeves’ November 26 budget may lack credible tightening measures. The global growth divergence, U.S. moderating, Europe stagnating, Asia stabilizing, suggests currency and trade dynamics will increasingly influence Fed calculus.
Nuclear Energy: The Supply Squeeze Intensifies
Uranium markets signaled structural tightness this week, with the long-term indicator hitting $86.00 per pound U₃O₈, a 17-year high. Spot futures at $80.80 reflect a 3% year-over-year gain despite recent consolidation from September’s $83.50 peak. The $18.40/lb spread between March lows and September highs captures the market’s recognition that supply can’t accommodate accelerating reactor construction.
Policy accelerants: The Trump administration’s $80 billion Westinghouse contract for large-scale reactor construction and uranium’s reinstatement to the 2025 Critical Minerals List demonstrate bipartisan commitment to domestic supply chain independence. Kazakhstan’s Kazatomprom formalized a strategic partnership with Jordan Uranium Mining Company, while Russia’s Rosatom and China’s CNNC expanded cooperation on training and skill development, highlighting the geopolitical dimension of nuclear fuel security.
Company-specific catalysts: BWXT Technologies secured a sole-source $1.5 billion NNSA contract for a domestic uranium enrichment pilot plant in Tennessee, tasked with producing both low-enriched uranium for tritium and high-enriched uranium for naval propulsion. This isn’t a commercial supply play, DUECE explicitly excludes power generation, but it establishes BWXT as the cornerstone of U.S. defense nuclear fuel infrastructure.
TerraPower advanced its Natrium reactor procurement, awarding three supplier contracts for its Kemmerer, Wyoming project (targeting 2030 completion) while simultaneously exploring Utah siting opportunities with the Office of Energy Development. The dual-track approach suggests confidence in regulatory momentum and reflects the $5 million in state-level technical assistance grants now available for early site permitting.
Equity performance: The VanEck Uranium and Nuclear ETF surged 49% year-to-date, with analysts highlighting Talen Energy (TLN) as particularly well-positioned given its 20-year power purchase agreements with Microsoft and Meta for nuclear-supplied data center capacity. The stock’s 81% YTD gain reflects investor recognition that AI’s energy demands require baseload nuclear solutions.
Investment Implication: The uranium supply deficit, projected to reach 184 million pounds by 2035, provides fundamental support for sustained price appreciation. Mid-$80s pricing offers sustainable economics for producers while remaining cost-competitive for generators. The policy landscape, particularly efforts to add 300 GWe by 2050, creates a multi-decade demand curve that mining companies have only begun to address.
Healthcare: Defensive Rotation Meets M&A Revival
November’s sector rotation has been unmistakable: the S&P 500 Health Care Index gained 5% while the broader market fell over 4%. Healthcare Select Sector SPDR (XLV) attracted its largest weekly inflows since January 2021, with investors paying 20x forward earnings versus 30x for technology.
Performance drivers: Eli Lilly (LLY) leads the complex, up on obesity/diabetes momentum and pipeline breadth. Amgen (AMGN) and Regeneron (REGN) have posted strong gains, while the healthcare equipment and services subsector outperformed pharmaceuticals by 28 basis points on November 18.
M&A accelerates: Johnson & Johnson (JNJ) acquired Halda for $3 billion to advance precision cancer cell therapy capabilities. ABL Bio’s bispecific antibody platform attracted a $2.6 billion licensing deal with Eli Lilly, pushing founder Lee Sang-hoon’s net worth past $1 billion. Solve Therapeutics secured $120 million to advance next-generation ADCs with novel linker technology. These transactions reflect Big Pharma’s urgency to fill looming loss-of-exclusivity gaps through targeted bolt-ons.
Regulatory catalysts: The FDA approved Regeneron’s high-dose Eylea formulation, bolstering its ophthalmology franchise despite outstanding manufacturing concerns. Arrowhead Pharmaceuticals awaits a November 18 decision on Plozasiran for familial chylomicronemia syndrome (the decision date has passed, but the setup illustrates the regulatory environment). More broadly, the agency proposed guidance to accelerate biosimilar development, though patent thickets continue blocking market entry.
Innovation landscape: The GenScript Biotech Global Forum in London highlighted the shift toward in vivo CAR-T engineering to reduce manufacturing complexity and costs. Separately, the Army’s Janus Program announced next steps for next-generation nuclear energy applications in defense contexts, though this remains early-stage.
Investment Implication: Healthcare’s defensive characteristics, non-discretionary demand, predictable cash flows, and attractive relative valuations, position it as a portfolio anchor during periods of macro uncertainty. The M&A cycle, combined with improving biotech sentiment (XBI’s rebound off lows), suggests alpha generation potential beyond simple sector rotation. Quality-tilted positions in market leaders with deep pipelines offer the best risk-adjusted exposure.
Looking Ahead: Key Events for Week of November 24
Macro: Markets operate on a shortened Thanksgiving schedule (closed Thursday, half-day Friday) with reduced liquidity likely amplifying volatility. The Fed blackout period begins Saturday, eliminating official communication until the December 10 FOMC meeting. UK Chancellor Reeves delivers the budget on November 26, with gilt markets pricing fiscal credibility concerns.
Earnings: The calendar includes Deere, Zoom, and a handful of healthcare names, though volume thins ahead of the holiday. McKesson (MCK) reports quarterly earnings expected at $9.00/share on $104.34 billion revenue.
Healthcare: Watch for FDA decisions on remaining November catalysts and further M&A announcements as companies seek to deploy capital before year-end. The Philadelphia biotech hub opening signals continued infrastructure buildout for early-stage companies.
Nuclear: Uranium price action will be monitored, above $85/lb resistance. TerraPower’s Utah siting assessment timeline (preliminary recommendations due year-end) could generate regional utility interest.
Portfolio Positioning
The confluence of Fed uncertainty and sector rotation argues for a barbell approach: maintain quality healthcare exposure for defensiveness while selectively adding nuclear names with idiosyncratic catalysts. BWXT’s government-mandated monopoly on defense enrichment and Talen’s data center contracts offer policy-insulated growth. In healthcare, focus on companies with late-stage pipeline assets or proven M&A appeal, Lilly’s execution on incretins, Amgen’s T-cell therapy optionality, and selective biotech names showing clinical momentum.
Volatility likely persists until December’s data deluge and Fed resolution. Use weakness to build positions in structural winners while hedging broad market exposure through the uncertainty window.